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Available online 10 April 2016Background: The present study evaluates the safety and efficacy of the Adipose Graft Transposition Procedure
(AGTP) as a biological regenerative innovation for patients with a chronic myocardial scar.
Methods: This prospective, randomized single-center controlled study included 10 patients with established
chronic transmural myocardial scars. Candidates for myocardial revascularization were randomly allocated
into two treatment groups. In the control arm (n = 5), the revascularizable area was treated with CABG and
the non-revascularizable area was left untouched. Patients in the AGTP-treated arm (n = 5) were treated with
CABG and the non-revascularizable area was covered by a biological adipose graft. The primary endpoint was
the appearance of adverse effects derived from the procedure including hospital admissions and death, and
24-hour Holter monitoring arrhythmias at baseline, 1 week, and 3 and 12 months. Secondary endpoints of effi-
cacy were assessed by cardiac MRI.
Findings: No differences in safety were observed between groups in terms of clinical or arrhythmic events. On
follow-upMRI testing, participants in theAGTP-treated arm showed a borderline smaller left ventricular end sys-
tolic volume (LVESV; p=0.09) and necrosis ratio (p=0.06) at 3months but not at 12months. TheAGTP-treated
patient with the largest necrotic area and most dilated chambers experienced a noted improvement in necrotic
mass size (−10.8%), and ventricular volumes (LVEDV:−55.2 mL and LVESV:−37.8 mL at one year follow-up)
after inferior AGTP.
Interpretation: Our results indicate that AGTP is safe and may be efficacious in selected patients. Further studies
are needed to assess its clinical value. (ClinicalTrials.org NCT01473433, AdiFlap Trial).








Cardiovascular disease remains themost common cause ofmortality
worldwide, accounting for more than 17 million deaths annually
(Anon., 2011). Myocardial infarction (MI) leads to irreversible myocar-
dial sequelae, often causing debilitating symptoms and shortening
life span. Recently, biological regenerative innovations have beenardiac Regeneration) Research
ujol University Hospital, Crta.
ayes-Genis).
. This is an open access article underintroduced as promising therapeutic options (Soler-Botija et al., 2012;
Gálvez-Montón et al., 2013a; Prat-Vidal et al., 2014).
Cardiac fat contains a population of mesenchymal-like progenitor
cells capable of differentiating into cells that closely resemble
cardiomyocytes, both morphologically and molecularly. In murine MI
models, these cells improved cardiac function parameters and promot-
ed local neoangiogenesis under hypoxia (Bayes-Genis et al., 2010). The
adipose tissue surrounding the heart and pericardium may serve as an
autologous biological matrix for salvaging injured myocardium.
The Adipose Graft Transposition Procedure (AGTP) uses patient's
existing cardiac fat directly, placing it over the myocardial infarcted
zones, rather than explanting a cardiac adipose biopsy to retrieve the
cells (Gálvez-Montón et al., 2011; Gálvez-Montón et al., 2013b). In thethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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LVEF in the AGTP-treated arm five-fold higher than untreated animals
(Gálvez-Montón et al., 2011). In the chronic MI porcine model, mor-
phometry revealed a 34% reduction in left ventricular infarct area of
AGTP-treated relative to control animals (Gálvez-Montón et al.,
2013b). These preclinical studies in a large mammal model suggest
that AGTP may be an effective post MI treatment for patients. Accord-
ingly, a prospective randomized trial was set up to assess safety and ef-
ficacy of AGTP in patients with a myocardial scar.
2. Patients and Methods
2.1. Patients
The study included 10 candidates for myocardial revascularization
with an established chronic transmural myocardial scar, from January
2012 to November 2013. Inclusion criteria included patients ≥18 years
of age, with an established transmural MI (minimum three months
old) anatomically non amenable for surgical revascularization, and can-
didates for coronary artery bypass graft (CABG) surgery of other arteries
non responsible for the transmural scar. A non-revascularizable area
was defined as a chronic transmural necrosis detected by means of
late gadolinium enhancement N70% of myocardial thickness on MRI.
Exclusion criteria were: severe valvular disease apt for surgery, can-
didates to surgical ventricular remodeling, contraindication for MRI,
extra-cardiac disease with life expectancy b1 year, severe renal or he-
patic insufficiency, previous cardiac surgery, very high surgical risk by
EuroSCORE (N8), and pregnant or breastfeeding women.
2.2. Study Design and AGTP Intervention
This study was a prospective, single-center, randomized controlled
phase I\\II clinical trial (ClinicalTrials.gov number NCT01473433,
AdiFLAP Trial). It was designed and implemented in accordance with
the Declaration of Helsinki; informed consent was obtained from all
participating patients.
Enrolled patients were randomly allocated in 2 arms (Fig. 1):
– Control arm (n = 5): Patients in whom the revascularizable area
was treated with CABG and the non-revascularizable area was left
untouched.
– AGTP-treated arm (n = 5): Patients in whom the revascularizable
area was treated with CABG and the non-revascularizable area was
covered by an autologous pericardial adipose graft. Fig. 2 summa-
rizes the steps of the AGTP intervention. First, to obtain the graft,
the pericardial adipose tissue was detached with its vascularization
intact (depending on scar location, the adipose tissue was detached
from the left or the right side of the pericardium as needed);
next, after pericardiotomy, the vascular adipose graft was gentlyFig. 1. Study design. n: number of patients, CABG: coronary artery bypass graft, AGpositioned to ensure full coverage of the necrotic zone; finally, to se-
cure the flap, the edges were adhered to bordering healthy myocar-
dium with commercially available cyanoacrylic-based surgical glue
(Glubran®2, USA) (Gálvez-Montón et al., 2011; Gálvez-Montón
et al., 2013b; Bagó et al., 2013; Roura et al., 2015).
The clinical cardiologist handling postsurgical care and theMRI spe-
cialist were both blind to the participants' treatment. Study visits
consisted of a baseline visit (obtained informed consent and performed
clinical assessment, includingMRI), surgical intervention, and follow-up
visits at one week (clinical assessment), three and 12 months (clinical
assessment including MRI) after procedure.
Safety of the procedurewas evaluated by the presence of major clin-
ical events including hospital admissions and death, and by the results
of a 24-hour Holter monitor test done at each study visit to assess ar-
rhythmias. Efficacy was assessed by left ventricular ejection fraction
(LVEF), cardiac output (CO), stroke volume (SV), end-diastolic wall
mass (EDWM), left ventricular end-diastolic (LVEDV) and end-systolic
volume (LVESV) by means of cardiac-MRI. NTproBNP, troponin I (TnI),
NYHA functional class and Framingham derived clinical score were
also assessed.
2.3. Cardiac MRI Data Acquisition and Analysis
All imaging were performed in a state-of-the-art 1.5 T clinical imag-
ing system (Avanto; Siemens Medical Imaging, Erlangen, Germany)
with the patient in the supine position and a 16-element phased-array
coil placed over the chest. Images were acquired during breath-holds
with ECG gating. We used a segmented k-space steady-state free-
precession sequence [RT 44.70 ms; echo time 1.26 ms; flip angle 78;
matrix 272; spatial resolution (1.3–1.5)×(1.3–1.5) × 8 mm depending
on the field of view] for cine imaging in parallel short-axis (contiguous
slices of 8-mm thickness covering from base to apex) and 3 long-axis
views of the left ventricle. Delayed enhancement images were acquired
with a segmented gradient-echo inversion-recovery sequence [RT
(600–800) ms depending on the cardiac heart rate; echo time 3.24 ms;
flip angle 25; matrix 256; spatial resolution 1.3 × 1.3 × 8 mm] at
matching cine-image slice locations 10 to 20 min after intravenous
gadolinium-DTPA administration (0.20 mmol/kg; Gadovist, Bayer
Schering Pharma AG, Berlin, Germany) (Simonetti et al., 2001). We opti-
mized the inversion time to null the normal myocardium and adjusted
views per segment and trigger delay according to the patient's heart
rate. Native and post contrast cardiac T1 mapping was calculated using
a modified Look–Locker inversion recovery sequence (MOLLI) in a
short axis view at the infarct level (Moon et al., 2013; White et al.,
2013; Messroghli et al., 2004, 2007).
All images were reviewed and analyzed off-line with a specialized
post-processing software (QMass-MR, v.7·0; Medis Medical ImagingTP: Adipose Graft Transposition Procedure, MRI: magnetic resonance imaging.
Fig. 2. Schematic illustration of the Adipose Graft Transposition Procedure (AGTP). Pericardial adipose tissue is dissected to create the graft (A). After partial pericardiectomy,MI is located
(B) and the pericardial adipose graft is transposed onto the infarct area and glued on healthy edges (C), covering the ischemicmyocardium (D). The figure was designed and hand-drawn
by CG-M.
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collected and interpreted all imaging data blinded to the clinical data
and outcome (J.A.S., A.R.: ICICORELAB, Valladolid, Spain; A.T.). LV endo-
cardial border (papillarymuscles were excluded)weremanually traced
on all short-axis cine images at the end-diastolic and end-systolic
frames to determine the LV end-diastolic and LV end-systolic volumes,
respectively. LVmasswas calculated by subtracting the endocardial vol-
ume from the epicardial volume at end diastole and thenmultiplying by
the tissue density (1.05 g/mL) (Kramer et al., 2008).
The endocardial and epicardial contours on delayed enhancement
images were also outlined manually. ROIs were then manually traced
in the hyperenhanced area at place of maximum signal intensity and
in the normal-appearing remote myocardium. As previously described,
the areas of hyperenhancingmyocardiumwere then automatically seg-
mented by using a full-width at half-maximum (FWHM) algorithm
(Flett et al., 2011; Amado et al., 2004). Two corrections were required
for all automated ROIs. First, microvascular obstruction (defined as
hypointensitywithin a hyperintense region in patientswith infarctions)
was adjusted to be included as late gadolinium enhancement (LGE) if
present. Second, any obvious blood pool or pericardial partial voluming
and artefacts were further removed from the ROI.
Scar volume for each slice was calculated as: area scar × slice thick-
ness. The scarmasswas expressed as total scar volume×1.05 g. The scar
percentage of myocardium was also expressed as a percentage of the
total myocardial volume: volume scar / volume myocardium × 100.
T1 mapping derived extracellular volume (ECV) of the necrotic area
was estimated using the native and post-contrast myocardial and blood
pool T1 maps, accounting for the patient hematocrit at the time of
exploration. The T1 map ROI was manually traced covering the entire
necrotic area avoiding any blood pool or pericardial partial voluming
or artefact. Moreover, areas of microvascular obstruction or fattyinfiltration were excluded from the T1 mapping calculation in order to
avoid any bias (Kellman et al., 2015).
2.4. Statistical Analysis
Descriptive analyses were performed at the first step. Categorical
variables were described by frequencies and percentages. Continuous
variables were described bymeans and standard deviations or medians
and interquartile ranges in cases of skewed distribution. Differences be-
tween groupswere compared using Student's t-test or one-way ANOVA
for multiple comparisons, with Tukey's test for post hoc analyses. The
comparison of continuous variables between groups was performed
using analysis of variance for unpaired data once normalitywas demon-
strated (Kolmogorov–Smirnov test); otherwise, a nonparametric test
(Mann–Whitney or Kruskal–Wallis test) was used. MRI data were ana-
lyzed as repeated measures using ANOVA with Greenhouse–Geisser
correction. A 2-sided p b 0.05 was considered significant. Statistical
analyses were performed using SPSS statistical package 19.0.1 version
(SPSS Inc, Chicago, IL, USA).
2.5. Role of the Funding Source
The funding sources had no such involvement.
3. Results
Tenpatientswere included, randomly allocated to control (n=5) or
AGTP-treated (n = 5). One patient in the control group (Patient #2)
was excluded after randomization because of MRI claustrophobia,
resulting in a total sample size of n = 9. All patients were men and
there were no significant differences between groups in clinical
Table 1
Baseline clinical and MRI variables of the studied population.
AGTP-treated Control
p-Value
N = 5 N = 4
Age 63.8 ± 13 60.3 ± 6 0.6
Risk factors
Smoking current/past 2 (40)/3 (60) 3 (75)/1 (25) 0.3
Hypertension 4 (80) 2 (50) 0.3
Diabetes 1 (20) 2 (50) 0.3
Dyslipidemia 4 (80) 1 (25) 0.1
HR 63 ± 7 61 ± 7 0.6
Q wave in ECG 4 (80) 2 (50) 0.3
NYHA I/II/III 0/4 (80)/1 (20) 1 (25)/2 (50)/1 (25) 0.6
NTproBNP 1066 ± 1084 1583 ± 1920 0.7
Peak TnI 3.1 ± 2.8 3.7 ± 2 0.7
Surgical variables
EuroSCORE 5.4 ± 2.5 3.5 ± 1 0.2
Logistic EuroSCORE, % 5.8 ± 4 2.9 ± 1 0.2
Logistic EuroSCORE II, % 3.1 ± 2.3 1.8 ± 0.9 0.3
Extracorporeal Circ. Time, min 76 ± 13 64 ± 23 0.4
Ischemia time, min 37 ± 25 30 ± 20 0.7
Grafts, no. 2.2 ± 0.8 2.0 ± 0.8 0.7
MRI variables
Necrosis mass, gr 34 ± 13 25 ± 4 0.2
Necrosis ratio, % 22 ± 9 18 ± 3 0.4
LVEF, % 41 ± 18 42 ± 15 0.9
LVESV, mL 140 ± 83 128 ± 61 0.8
LVEDV, mL 220 ± 80 212 ± 46 0.8
CO, L/min 5.0 ± 0.8 5.1 ± 1.3 0.9
Data expressed in mean and standard deviation.
AGTP: Adipose Graft Transposition Procedure; HR: heart rate; NYHA: New York Heart As-
sociation; NTproBNP: N-terminal pro-B-type natriuretic peptide; ECG: electrocardiogram;
TnI: Troponin I; LVEF: left ventricular ejection fraction; LVESV: left ventricular end systolic




N = 5 N = 4
Total adverse events 3 2 0.8
Death 1 0 0.6
Hospital admission 1 1 0.7
New supraventricular arrhythmiasa 0 0
New ventricular arrhythmiasa 1 1 0.9
Changes in number of SVEBb +30 ± 28 +209 ± 731 0.7
Changes in number of VEBb −331 ± 280 −158 ± 218 0.3
AGTP: Adipose Graft Transposition Procedure; SVEB: supraventricular ectopi beats; VEB:
ventricular ectopi beats.
a Tachycardia defined as three or more beats, taking as reference the pre-intervention
24-h Holter monitoring. Ventricular arrhythmias were asymptomatic non-sustained
monomorphic ventricular tachycardia.
b Mean number from post-intervention Holter vs. pre-intervention Holter.
251A. Bayes-Genis et al. / EBioMedicine 7 (2016) 248–254variables, nor in variables related to disease severity or surgical risk
(Table 1).
The same surgeon performed all interventions (M.C.). Patency of all
grafts was confirmed and no adverse events were detected during sur-
gery. Table 2 summarizes the surgical characteristics of study patients
and Video 1 shows an inferior AGTP.
No differences in procedure safety were observed between groups
(Table 3). Unrelated to the procedure, one patient died in the AGTP-
treated arm after seven months due to colonic adenocarcinoma. There
were no differences in hospital admissions during follow-up identified
between groups. One hospital admission was registered in each
group: in the control arm due to symptomatic hypotension and in the
AGTP-treated arm for colonic resection, respectively. 24-hour Holter
monitoring during 1-year follow-up showed non-significant differences
in arrhythmia prevalence, although the number of supraventricular
ectopi in the AGTP-treated arm was reduced (Table 3).
Relative changes in percentage of necrotic tissue from baseline
to three months in AGTP-treated and control patients assessed by
MRI are shown in Fig. 3. Table 4 shows MRI cardiac function data.
Overall, we did not observe significant differences between groups.Table 2
Patient interventional characteristics.
Patient EuroSCORE Logistic EuroSCOREa Logistic EuroSCORE IIa ECC
1 3 2.40% 1.16% Yes
3 8 10.19% 6.69% Yes
4 4 3.51% 2.39% No
5 3 2.07% 0.95% Yes
6 4 3.76% 1.89% Yes
7 8 10.06% 3.56% No
8 4 2.89% 2.44% Yes
9 5 4.38% 3.05% Yes
10 2 1.51% 0.58% Yes
ECC: extracorporeal circulation; AGTP: Adipose Graft Transposition Procedure.
a Percentage of predicted operative mortality for patients undergoing cardiac surgery by logHowever, Greenhouse–Geisser analyses, which include inter- and
intra-individual changes over time, did reveal a trend for smaller
LVESV (p = 0.09) and necrosis ratio (p = 0.06) in the AGTP-treated
arm at three months. Infarct site-derived T1 mapping extracellular vol-
ume (ECV) estimation revealed no significant reduction in the extracel-
lular space from baseline to 3-month follow-up in AGTP-treated versus
control patients (−4.5% vs. −1.1%, respectively; p = 0.53). No differ-
ences in NTproBNP, TnI, NYHA functional class and Framingham-
derived clinical score were found between groups.
One patient in the AGTP-treated arm experienced a remarkable im-
provement after inferior AGTP (Fig. 4). At the beginning of the study, he
had the largest necrotic area (LV necrotic mass: 33.2%) and themost di-
lated ventricular chambers (LVEDV: 315.1 mL; LVESV: 218.5 mL) of all
participants; 3 months after AGTP treatment LV necrotic mass was re-
duced by 4.4%, LVEDV by 31.9 mL, and LVESV by 23.8 mL. After one-
year follow-up, these numbers had decreased further to 10.8%,
55.2 mL, and 37.8 mL, for LV necrotic mass, LVEDV, and LVESV respec-
tively. Remarkably, Q waves vanished from leads I, II and III in the
follow-up ECGs (Fig. 4).
4. Discussion
The results of this pilot study in a prospective cohort indicate that
AGTP is a safe procedure that may be efficacious in selected patients.
Given its autologous nature and ease of implementation, the translation
of the AGTP technique to clinical practice should not be hampered
by technical difficulties, economic restrictions, nor ethical or social
considerations.
Themechanism of the positive effects of this biological innovation is
uncertain, but one possibility is the establishment of vascular connec-
tions between the adipose graft and the underlyingmyocardium as pre-
viously demonstrated in the swineMI model (Bayes-Genis et al., 2013).
There are few accepted techniques of vascularizing a damaged heart. In
brief, direct methods such as the simple insertion of an internal mam-
mary artery into the myocardium through a hole (Unger et al., 1990)ECC time Ischemia time No grafts Study arm AGTP location
92 62 3 AGTP Inferior
61 32 2 AGTP Inferior
– 0 1 Control –
81 57 3 AGTP Inferior
89 44 3 Control –
– 0 1 AGTP Inferior
44 32 2 Control –
70 32 2 AGTP Anterior
60 42 2 Control –
istic EuroSCORE I and II formulas.
Fig. 3.MRI analysis: Representative T1 short-axis delayed enhancement images rev`eal healthy (black) and infarctedmyocardium (white) for AGTP-treated and control patients at baseline
and 12 months. Arrowheads point out the attached adipose graft position in the treated patients. Histograms represent changes in percentage of necrotic tissue from baseline to three
months in treated and control patients.
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soids observed in reptilian hearts (Stone et al., 2002) have not demon-
strated a clear-cut clinical benefit. In contrast, indirect revascularization
of damaged organs with vascular grafts has been successfully achieved
(Rocha et al., 2007; Motegi et al., 2007). Previous reports indicate that
following AGTP new microvessels developed, bridging the interface
between the adipose vascular graft and adjacent myocardium
(Gálvez-Montón et al., 2011; Gálvez-Montón et al., 2013b) thus enabling
an exchange of nutrients and progenitors between the biological adipose
graft and the underlying myocardial scar.
It is unclear whether the adipose-derived progenitor cells exert a
role in the beneficial effect of the AGTP. Recent data suggested that car-
diac adipose-derived progenitors have an inherent cardiac-like pheno-
type and may support heart homeostasis, perhaps as a cell reservoir
for renewing myocardial tissue. Indeed, in vivo studies in murine
models have clearly shown that cardiac adipose-derived progenitorsTable 4
Mean MRI values at baseline, three months and one year follow-up.
AGTP-treated
Baseline 3 months 12 m
Necrosis mass, gr 33.9 32.9 30.
Necrosis ratio, % 22.3 20.1 19.
LVEF, % 41 43 47
LVESV, mL 139.6 131.9 114.
LVEDV, mL 219.8 218.0 202.
CO, L/min 5.0 5.5 5.
SV, mL 80.2 87.3 87.
Data expressed in mean and standard deviation. No statistically significant differences were ob
AGTP: Adipose Graft Transposition Procedure; LVEF: left ventricular ejection fraction; LVESV: lef
output; SV: stroke volume.displayed a beneficial effect in the context ofMI. Cell transplantation re-
sulted in improved cardiac function parameters and was associated
with a significant increase in infarct-related wall thickness (Bayes-
Genis et al., 2010). In pre-clinical studies in the porcine model, cell traf-
ficking from the adipose graft to the infarctedmyocardiumwas also ob-
served (Gálvez-Montón et al., 2011). Finally, adipokines liberated by the
graft may exert a positive local effect and should be considered as an al-
ternative mechanism. Many studies have described the myocardium
and perivascular adipose tissue as well-known sources of hormones,
which might exert important autocrine, paracrine, and endocrine ef-
fects (Ahima and Flier, 2000). Indeed, evidence suggests that adipose-
derived hormones can offer cardio-protective effects, including attenu-
ation of cardiomyocyte apoptosis, reduction of infarct size, andmodula-
tion of collagen I/III ratios (Sweeney, 2010).
Identification of AGTP responders is an unresolved challenge, but
may ultimately be the key to explaining the case of the AGTP-treatedControl
onths Baseline 3 months 12 months
0 25.2 23.8 22.4
3 18.4 20.2 17.8
42 47 46
9 127.8 99.2 104.6
4 212.2 187.7 194.6
8 5.1 5.9 5.5
5 84.4 88.5 90.1
served.
t ventricular end systolic volume; LVEDV: left ventricular end diastolic volume; CO: cardiac
Fig. 4. Selected patient case: short-axis delayed enhanced images show the healthy (black) and infarcted myocardium (white) before and after AGTP; 4-chamber view shows patient's
volumes before and after AGTP. Arrows point out the attached adipose graft position in the treated patient. ECG shows a Q wave in leads III and aVF at baseline that is not present at
follow-up ECGs.
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strated the most severe indicators at the start of the study, experienced
the greatest improvement after AGTP treatment. Further research is re-
quired to identify the clinical, biochemical and/or MRI characteristics of
AGTP optimal candidates.
AGTP-treated patients showed a trend towards smaller ventricular
volumes than the control group. These results should be interpreted
with caution; nevertheless it is plausible that AGTP exerted some bene-
ficial effect by the adiposematrixwrapping the infarcted area. However,
the associated CABGprocedure practiced in these patients should not be
discarded.
This study has several limitations. It was a pilot study with a small
number of enrolled subjects, limiting our ability to generalize findings
to the overall population. We were not able to perform an autopsy of
the deceased patient to confirm proper apposition of the graft nor for
additional studies at the ultrastructural level. However, the derived T1
mapping ECV estimation may reflect an improvement in scar composi-
tion. Furthermore, future MRI software refinements may allow a more
precise definition of the adipose graft surrounding the heart.
At present, cell therapy has been themost tested biological approach
for cardiac regeneration/recovery in humans. Cell therapy is safe, but
with controversial benefits measured in surrogate endpoints such as
LVEF. The recent multicenter, prospective, randomized open-label
TECAM trial evaluated three different bone marrow-derived stem cell
approaches in MI (intracoronary bone-marrow mononuclear cell —
BMMC— injection; mobilization with G-CSF; and both BMMC injection
plus G-CSF), none ofwhich resulted in improvement of LVEF or volumes
compared with standard MI care (San Roman et al., 2015).
This is the first-in-man study onmyocardial adipose grafting andwe
should be restrained in interpreting the results, but findings suggest an
improvement in necrosis area in AGTP-treated patients during early
follow-up. Future studies are needed to determinewhether this innova-
tion translates to superior cardiac function with longer follow-up. This
study provides evidence that use of an autologous vascular adipose
graft may be a safe alternative in patients with a chronic myocardial
scar. A Phase II\\III multicenter, prospective, randomized clinical trial
is now being set-up to confirm efficacy of the AGTP intervention.Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2016.03.027.
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